Arrhythmia Risk Assessment

Arrhythmia Risk Assessment designates comprehensive evaluation of pharmaceutical candidates' potential to cause cardiac rhythm disturbances, particularly QT interval prolongation predisposing to potentially fatal torsades de pointes arrhythmia, through integrated nonclinical and clinical studies informing safety decisions throughout development.

The pharmaceutical industry implements rigorous arrhythmia risk assessment following ICH E14 and S7B guidelines. In vitro hERG channel assays detect potassium channel inhibition predicting QT effects. Cardiomyocyte action potential studies assess integrated cardiac electrophysiology. In vivo cardiovascular safety pharmacology evaluates rhythm effects in animal models. Clinical QT assessment employs concentration-QTc modelling from early phase studies. Regulatory submissions require comprehensive cardiac safety packages. As integrated risk assessment approaches mature, replacing definitive thorough QT trials through exposure-response modelling becomes increasingly accepted, streamlining development while maintaining patient safety standards through a science-based approach.